Source: International Congress 2015 – New insights into IIPs



Rating:

Share or cite this content

Citations should be made in the following way:
Nicolas Petitpierre (Bursins, Switzerland), Nicolas Petitpierre, Romain Lazor, Sylvain Marchand-Adam, Vincent Cottin, Isabelle Court-Fortune, Sandrine Hirschi, Dominique Rigaud, Stéphane Jouneau, Jean-François Cordier, The Groupe d’Etudes et de Recherche sur les Maladies ²Orphelines². A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia. Eur Respir J 2015; 46: Suppl. 59, 4855

Member's Comments

No comment yet.

Related content which might interest you: Cryptogenic organizing pneumonia – Results of treatment with clarithromycin versus corticosteroids Source: International Congress 2016 – Orphan diseases II Year: 2016 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Treatment of exacerbations of fibrotic idiopathic interstitial pneumonias with cyclophosphamide and corticosteroids Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Treatment results using low doses of prednisolone, cyclophosphamide and extracorporeal processing of lymphocytes with prednisolone in patients with idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003 Colchicine, prednisone versus no therapy in idiopathic pulmonary fibosis Source: Eur Respir J 2006; 28: Suppl. 50, 744s Year: 2006 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Effect of pirfenidone on chronic interstitial pneumonia Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005